LIANG Nai-xin, MEI Shi-qi. The Application of Icotinib as Adjuvant Therapy for Stage Ⅱ~ⅢA EGFR-Mutant Non-Small-Cell Lung Cancer[J]. Journal of Evidence-Based Medicine, 2022, 22(1): 34-37. DOI: 10.12019/j.issn.1671-5144.2022.01.008
|
Citation:
|
LIANG Nai-xin, MEI Shi-qi. The Application of Icotinib as Adjuvant Therapy for Stage Ⅱ~ⅢA EGFR-Mutant Non-Small-Cell Lung Cancer[J]. Journal of Evidence-Based Medicine, 2022, 22(1): 34-37. DOI: 10.12019/j.issn.1671-5144.2022.01.008
|
LIANG Nai-xin, MEI Shi-qi. The Application of Icotinib as Adjuvant Therapy for Stage Ⅱ~ⅢA EGFR-Mutant Non-Small-Cell Lung Cancer[J]. Journal of Evidence-Based Medicine, 2022, 22(1): 34-37. DOI: 10.12019/j.issn.1671-5144.2022.01.008
|
Citation:
|
LIANG Nai-xin, MEI Shi-qi. The Application of Icotinib as Adjuvant Therapy for Stage Ⅱ~ⅢA EGFR-Mutant Non-Small-Cell Lung Cancer[J]. Journal of Evidence-Based Medicine, 2022, 22(1): 34-37. DOI: 10.12019/j.issn.1671-5144.2022.01.008
|
DownLoad: